Condition
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07538518Not Yet RecruitingPrimary
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels
NCT07116473Phase 3Not Yet Recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT03336580Phase 1TerminatedPrimary
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Showing all 3 trials